The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Share News (EVG)

  • There is currently no data for EVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Apax opts against lifting offer; DCI enters loan deal

Fri, 09th Feb 2024 18:53

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

----------

RTW Biotech Opportunities Ltd - New York-based investment firm focused on the life sciences sector - Notes announcement by Kyverna Therapeutics regarding its pricing of a USD319 million initial public offering, upsized USD137 million above its initial estimate last week. Kyverna is a clinical-stage cell therapy biopharma company, in which RTW initially invested through a Series B funding round in early 2022. On the first day of trading, Kyverna's share price traded up by 36% to close at USD30.00 per share.

----------

Symphony Environmental Technologies PLC - Hertfordshire-based firm developing technology to make plastic biodegradable - Says that the General Court of the European Union found that the defendants didn't exceed "the limits of their discretion", so Symphony is not entitled to compensation. However, Symphony explains that the judgement was not an assessment of the effectiveness of the d2w technologies. Adds that the court didn't include further studies that have supported the technology, as well as the distinction between oxo-biodegradable and oxo-degradable plastics. Says that d2w technology has not been widely used in the EU for several years, and the lengthy legal process and judgment has "very little effect" on existing business.

----------

Evgen Pharma PLC - clinical stage drug development company developing sulforaphane-based medicines - Notes dispute with Stalicla SA, its partner in autism spectrum disorder and other neurodevelopmental disorders. Explains that in October 2022, Evgen licensed the rights for its lead asset, SFX-01, to Stalicla for up to USD160.5 million in milestone payments. An initial USD500,000 was paid upfront with the next anticipated payment of USD500,000 due on completion of the Evgen-sponsored human volunteer Phase 1 study. Evgen, having completed a Phase 1b study, believes the next payment is now due, and says it has formally implemented the dispute resolution process. It had not anticipated any milestone payments from Stalicla in its financial forecasting, and its cash runway remains unchanged.

----------

Substrate Artificial Inteligence SA - Madrid-based incubator of companies providing artificial intelligence products and services in fintech, agritech, energy, human resources, and health sectors - Signs investment deal with Indico Investments and Management SL, for a maximum of EUR2.0 million. The investment commitment, which expires on February 7, relates to the company's Class A shares. It will be carried out in tranches of EUR500,000, with a discount of 10%.

----------

DCI Advisors Ltd - British Virgin Islands-based real estate investment company - Says it has entered another loan agreement for EUR350,000 with a shareholder to provide additional working capital. The shareholder providing this loan previously entered into a loan agreement with DCI Advisors for EUR350,000 last October. To date, DCI has received seven loans of EUR350,000 each and two loans from funds managed by a single shareholder amounting to USD330,000 in aggregate.

----------

Apax Global Alpha Ltd - Guernsey-based investor in technology, services, healthcare, internet and consumer - Confirms that the offer of 120 pence in cash per Kin and Carta PLC share is final and will not be increased. In December, Apax said that a 'no increase statement' relating to its own offer price was no longer in effect and had been set aside, after Kin & Carta accepted an offer of 130p per share from Valtech, a company controlled by funds advised by London-based BC Partners LLP.

----------

Sutton Harbour Group PLC - Plymouth, England-based waterfront regeneration specialist - Notes press statement made by Plymouth City Council on Thursday, and confirms that it has received a letter from the Council alleging a breach of the Plymouth City Airport lease. Says that it is considering, in conjunction with its advisers, the contents of the letter, and will provide an update in due course.

----------

By Holly Beveridge, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
20 Sep 2021 14:50

IN BRIEF: Evgen Pharma's SFX-01 effective on tumour cells

IN BRIEF: Evgen Pharma's SFX-01 effective on tumour cells

Read more
2 Sep 2021 11:56

IN BRIEF: Evgen SFX-01 granted orphan drug designation by US FDA

IN BRIEF: Evgen SFX-01 granted orphan drug designation by US FDA

Read more
13 Jul 2021 15:36

Evgen pleased with preclinical data on SFX-01

(Sharecast News) - Clinical-stage drug development company Evgen Pharma announced preclinical data demonstrating that 'SFX-01' was effective in in-vitro models of certain blood cancers on Tuesday.

Read more
13 Jul 2021 14:09

IN BRIEF: Evgen Pharma files brain tumour treatment request with FDA

IN BRIEF: Evgen Pharma files brain tumour treatment request with FDA

Read more
13 Jul 2021 11:25

IN BRIEF: Evgen Pharma encouraged by early data for SFX-01

IN BRIEF: Evgen Pharma encouraged by early data for SFX-01

Read more
13 Jul 2021 11:20

AIM WINNERS & LOSERS: Star Phoenix wins new deal; Ebiquity revenue up

AIM WINNERS & LOSERS: Star Phoenix wins new deal; Ebiquity revenue up

Read more
9 Jul 2021 11:51

Evgen Pharma halts trial as SFX-01 drug fails to help Covid patients

Evgen Pharma halts trial as SFX-01 drug fails to help Covid patients

Read more
9 Jul 2021 10:52

AIM WINNERS & LOSERS: Evgen disappointed as SFX-01 flops study hurdle

AIM WINNERS & LOSERS: Evgen disappointed as SFX-01 flops study hurdle

Read more
9 Jul 2021 10:33

Evgen 'surprised and disappointed' by findings in SFX-01 trial

(Sharecast News) - Clinical-stage drug development company Evgen Pharma announced the results of the interim safety and futility assessment readout of the first 100 patients treated in the 'STAR' Covid-19 trial of its lead asset, 'SFX-01', on Friday.

Read more
6 Jul 2021 16:10

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

Read more
15 Jun 2021 14:42

TRADING UPDATES: GB Group rebuilds dividend; IPF ups 2021 profit view

TRADING UPDATES: GB Group rebuilds dividend; IPF ups 2021 profit view

Read more
14 Jun 2021 13:19

TRADING UPDATES: Synectics loss narrows; Active Energy loss widens

TRADING UPDATES: Synectics loss narrows; Active Energy loss widens

Read more
14 Jun 2021 11:00

Evgen upbeat on new data on potential breast cancer treatment

(Sharecast News) - Clinical-stage drug development company Evgen Pharma announced new preclinical data on Monday, which showed 'SFX-01' could be of benefit to metastatic breast cancer (mBC) patients who had become resistant to CDK4/6 inhibitors.

Read more
26 Apr 2021 13:02

IN BRIEF: Evgen Pharma appoints Huw Jones as chief medical officer

IN BRIEF: Evgen Pharma appoints Huw Jones as chief medical officer

Read more
7 Apr 2021 16:22

IN BRIEF: Evgen Pharma notes publication on sulforaphane in Covid-19

IN BRIEF: Evgen Pharma notes publication on sulforaphane in Covid-19

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.